Back to Search
Start Over
Cost‒utility analysis of breast reduction surgery for women with symptomatic breast hypertrophy
- Source :
- Medical Journal of Australia. 216:147-152
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Objective To assess the cost-effectiveness of breast reduction surgery for women with symptomatic breast hypertrophy in Australia. Design Cost-utility analysis of data from a prospective cohort study. Setting, participants Adult women with symptomatic breast hypertrophy assessed for bilateral breast reduction at the Flinders Medical Centre, a public tertiary hospital in Adelaide, April 2007 - February 2018. The control group included women with breast hypertrophy who had not undergone surgery. Main outcome measures Health care costs (for the surgical admission and other related hospital costs within 12 months of surgery) and SF-6D utility scores (measure of health-related quality of life) were used to calculate incremental costs per quality-adjusted life-year (QALY) gained over 12 months, extrapolated to a 10-year time horizon. Results Of 251 women who underwent breast reduction, 209 completed the baseline and at least one post-operation assessment (83%; intervention group); 124 of 350 invited women waiting for breast reduction surgery completed the baseline and 12-month assessments (35%; control group). In the intervention group, the mean SF-6D utility score increased from 0.313 (SD, 0.263) at baseline to 0.626 (SD, 0.277) at 12 months; in the control group, it declined from 0.296 (SD, 0.267) to 0.270 (SD, 0.257). The mean QALY gain was consequently greater for the intervention group (adjusted difference, 1.519; 95% CI, 1.362-1.675). The mean hospital cost per patient was $11 857 (SD, $4322), and the incremental cost-effectiveness ratio (ICER) for the intervention was $7808 per QALY gained. The probability of breast reduction surgery being cost-effective was 100% at a willingness-to-pay threshold of $50 000 per QALY and 88% at $28 033 per QALY. Conclusions Breast reduction surgery for women with symptomatic breast hypertrophy is cost-effective and should be available to women through the Australian public healthcare system.
- Subjects :
- Adult
medicine.medical_specialty
Cost-Benefit Analysis
Mammaplasty
medicine.medical_treatment
Breast surgery
Breast hypertrophy
Breast Diseases
Quality of life
Health care
medicine
Humans
Breast
Prospective Studies
Prospective cohort study
Cost–utility analysis
business.industry
Australia
Health Care Costs
Hypertrophy
General Medicine
Middle Aged
medicine.disease
Surgery
Female
Quality-Adjusted Life Years
Breast reduction
Elective Surgical Procedure
business
Subjects
Details
- ISSN :
- 13265377 and 0025729X
- Volume :
- 216
- Database :
- OpenAIRE
- Journal :
- Medical Journal of Australia
- Accession number :
- edsair.doi.dedup.....2a9a006768ac2f1ba2ebb33109b6f6f3
- Full Text :
- https://doi.org/10.5694/mja2.51343